Related Experiment Video
Updated: Sep 4, 2025
10:47
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
8.9K
Antibody Engineering for Nuclear Imaging and Radioimmunotherapy
Cindy Rodriguez1,2,3, Samantha Delaney1,3,4, Samantha M Sarrett1,3,4
1Department of Chemistry, Hunter College, City University of New York, New York, New York.
Summary
Antibody engineering enhances radiopharmaceuticals for nuclear medicine imaging and therapy by improving drug delivery, targeting, and efficacy. This review highlights advances in optimizing radioimmunoconjugates for improved patient outcomes.
Area of Science:
- Nuclear Medicine
- Molecular Imaging
- Immunology
Background:
- Radiolabeled antibodies are crucial in nuclear medicine for diagnostics and therapeutics.
- Intrinsic antibody properties pose limitations for radiopharmaceutical development.
- Antibody engineering offers solutions to overcome these limitations.
Purpose of the Study:
- To review recent advancements in antibody engineering for nuclear medicine applications.
- To discuss how engineering improves radiolabeled antibodies for immunoPET, immunoSPECT, and radioimmunotherapy.
- To highlight key strategies for optimizing radioimmunoconjugates.
Main Methods:
- Focus on antibody engineering techniques applied to radiopharmaceuticals.
- Analysis of strategies for improving pharmacokinetics.
- Review of methods for site-specific bioconjugation and Fc interaction modulation.
- Exploration of bispecific antibody constructs.
Main Results:
- Engineering optimizes radioimmunoconjugates for improved pharmacokinetic profiles.
- Site-specific bioconjugation enhances radiolabeling efficiency and stability.
- Modulating Fc interactions influences biodistribution and effector functions.
- Bispecific constructs enable enhanced targeting and therapeutic potential.
Conclusions:
- Antibody engineering is vital for advancing radiopharmaceuticals in molecular imaging and radioimmunotherapy.
- Engineered antibodies offer improved targeting, pharmacokinetics, and therapeutic efficacy.
- Continued innovation in antibody engineering promises to expand the clinical utility of radiopharmaceuticals.
